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Exploring the potential of NTME/
GC-MS, in the establishment of 
urinary volatomic profiles. Lung 
cancer patients as case study
Priscilla Porto-Figueira1, Jorge Pereira1, Wolfram Miekisch2 & José S. Câmara  1,3
The growing cancer incidence and mortality worldwide claims for the development of novel diagnostic 
strategies. In this study we aimed to explore the potential of an innovative methodology, based on a 
needle trap microextraction (NTME), combined with gas chromatography-mass spectrometry (GC-MS), 
as new approach to isolate and profile urinary volatile organic metabolites (VOMs) from lung cancer 
(LC) patients and healthy individuals (CTRL). In this context, different experimental parameters with 
influence of NTME extraction efficiency including, temperature, equilibration time, headspace volume, 
ionic strength, pH, effects of sample volume and stirring, were investigated and optimized. For the 
DVB/CarX/Car1000 needle trap device (NTD), the best results were obtained using 40 mL headspace of 
a 4-mL acidified (pH = 2) urine sample with 20% NaCl and an extraction temperature of 50 °C for 40 min 
of equilibration time. The stability of the isolated VOMs was investigated up to 72 h after extraction. 
From the VOMs identified, belonging namely to ketones, sulphur and benzene derivatives, 98 presented 
a frequency of occurrence above 90%. Data were processed by discriminant analysis, retrieving 
differentiated clusters for LC and CTRL groups. As far we are aware, this is the first study using NTME/
GC-MS to establish urinary volatomic profiles. Preliminary results are very promising, as broad and 
comprehensive volatile profiles were obtained. Moreover, the extended storage stability of the NTD 
devices opens new opportunities for sampling other matrices in a wide range of applications.
According to the most recent statistic available data (WHO, 2012), cancer was the second leading cause of death 
from non-communicable diseases worldwide, accounting for 8.2 million deaths1. The increase of the disease 
is overwhelming, with 3 million new cases reported every year1. This has been possible because conventional 
diagnostic methods for cancer have high costs and most of them are also quite invasive, causing mental and 
physical discomfort to the patient and even some risks for his life. For these reasons, demand for non-invasive 
strategies, able to obtain early information, less expensive and more amenable to the patients are essential to 
improve long term survival rates and quality of life. The characterization of the human metabolome opens new 
diagnosis opportunities, particularly in the identification of potential new cancer biomarkers using non-invasive 
methodologies targeted for early diagnosis. The use of volatile organic metabolites (VOMs) can be useful for this 
purpose, as well for monitoring the disease throughout its development, recurrence or treatment2,3. Biological flu-
ids such us urine are rich in volatile compounds and this property has been used as a means of diagnosis, at least, 
since the ancient Greeks Hippocrates and Galen correlated the urinary odour with diabetes and kidney failure4. 
Theoretically, urinary volatomic profiles could be useful to characterize the disease itself as well as disease pro-
gression or response to therapy. In this context, VOMs identified in biological fluids, including urine, saliva and 
exhaled breath, constitute a very useful tool with potential to discriminate several diseases, including cancer2,5,6. 
However, due to the low concentration of most VOMs in the biofluids, the use of highly efficient extraction and 
analytical techniques able to isolate, identify and quantify these human metabolites, even at trace levels, is crucial 
for the success of such approach. Currently, methodologies as solid phase microextraction (SPME) combined 
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with gas chromatography-mass spectrometry (GC-MS) analysis, deliver reliable and reproducible VOMs profiles 
of different biological samples2,5–7 but simultaneously the availability of extraction materials and basic equilibra-
tion mechanisms make them very selective. Silva et al.5,6 demonstrated the potential of certain urinary VOMs 
to discriminate different types of cancer, including breast5 and colon6 cancer. Matsumura et al.8 also established 
differences between the urinary profiles of lung cancer (LC) model mice with mices without any disease. Needle 
trap microextraction (NTME) is an innovative alternative to the common equilibration-based microextraction 
methodologies used to obtain volatile fingerprints from different matrices. NTME combines the advantages 
offered by SPME and solid phase extraction (SPE)9, with robustness, by employing resistant needles, also known 
as Needle Trap Devices (NTDs). NTDs can be adapted to the properties of the target volatiles by means of com-
mercially available sorbent materials, particularly their affinity to the sorbent used (Fig. 1)10. Similarly to SPME, 
the technique requires small sample amounts, but the sensitivity of the methodology can be increased due to its 
exhaustive working mode10.
The objective of this work was to evaluate the potential of an innovative extraction methodology, NTME, 
combined with GC-MS and multivariate statistical analysis (MVSA) to establish the urinary volatomic patterns 
from LC patients and healthy subjects (CTRL) as a powerful platform to discriminate among LC and CTRL 
groups and identify putative volatile biomarkers. Different experimental parameters influencing the NTME effi-
ciency, namely the equilibrium time, temperature, headspace volume, ionic strength, sample volume and sample 
agitation, were investigated and optimized. In addition, the stability (time of storage) of the extracted VOMs in 
the NTDs was also evaluated.
Results and Discussion
Optimization of NTME Extraction Parameters. To improve the efficiency of the NTME for the isola-
tion of volatiles from headspace over urine samples, an univariate optimization strategy was applied to select the 
best conditions for a feasible and reliable experimental protocol. This approach follows previous work involving 
VOMs extraction from different biological matrices using SPME6,7,10. Accordingly, seven experimental param-
eters, sample volume, pH and ionic strength (% NaCl), temperature, headspace volume, equilibration time and 
stirring, were evaluated and optimized. The NTD configuration used was custom made triple layered DVB/CarX/
Car1000 (Shinwa Ltd. Japan - Fig. 1), which was previously shown to be particularly tailored for applications 
aiming a comprehensive volatile characterization of low volume, water-saturated samples10.
Sample pH. Previous studies have shown that the VOMs present in urine are mostly acidic5,6,11. Thus, the 
extraction efficiency will be greater if the metabolites are in their protonated form. On the other hand, many 
metabolites are eliminated through urine in conjugated forms, being also characterized by their low volatility 
and hydrophilic nature12. Rocha et al.11 have shown both the number of VOMs present in urine, as well as their 
associated relative areas, were higher in acidic conditions. In this work, we verified that urine acidification corre-
sponds to an increase in the VOMs extraction efficiency, both in the number of volatiles identified, as well as in 
terms of total peak area (Fig. 2A). These results are therefore very interesting and explained by the polar nature of 
the urinary volatiles which, in the protonated form, may diffuse more easily from the sample to the headspace. It 
is important to note that all the VOMs identified in the basified (using NaOH) and neutralized (using NaOH or 
HCl) samples, pH 11 and 7, respectively, were also found in the acidified (using HCl) urine samples (pH 2) with 
higher responses. The only exception to this observation was acetone (Supplementary Fig. 1). All subsequent 
extractions were therefore carried out using acidified urine samples (pH 2).
Figure 1. Configuration of the Needle Trap Device (NTD) used in this work. (A) Schematic representation 
of the triple bed DVB/CarX/Car1000 NTD, which allows the sequential retention from the big and polar 
to the small and less polar volatiles (DVB, divinylbenzene, is a week sorbent that retains mainly C7 to C20 
compounds; CarX, Carboxen X, is a middle strong sorbent with higher affinity for C3 to C8 volatiles; Car1000, 
Carbopack 1000, is the strongest sorbent, retaining mainly C2 to C6 compounds). (B) The experimental layout 
used, (C) the DVB/CarX/Car1000 NTD loading the extracted volatiles in the GC-MS.
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Extraction Temperature. The extraction temperature affects the extraction efficiency as higher temperatures 
facilitate the mass transfer of the compounds from the bulk sample to the headspace vapor phase. This increases the 
diffusion coefficient and decreases the distribution constant, reaching faster the balance between the two phases13,14. 
By increasing the temperature, we therefore can reduce the extraction time. This, however, is only valid until thermal 
degradation and/or isomerization of the sample metabolites occurs13. We have assayed extractions at 30 °C, 40 °C, 50 °C 
and 60 °C and the results shows a considerable increase in terms of number of extracted compounds and total area from 
30 °C up to 50 °C, but not a relevant gain from 50 °C to 60 °C (Fig. 2B). This result agrees with our previous work using 
other extraction methodologies for the characterization of urinary volatile profiles5,6. Based on the obtained results, 
50 °C was selected as the most appropriate temperature for the extraction of urinary volatile metabolites.
Ionic Strength. The addition of salt (NaCl) to urine samples increases the ionic strength, enhancing the 
salting-out effect during the extractive process and therefore facilitating the diffusion of metabolites to the vapor 
phase12,13. On the other hand, excess of salts in solution do not favour the extraction13. In fact, we obtained a gain 
in the extraction efficiency with ionic strengths up to 20% NaCl (w /v). At higher NaCl concentrations (30% NaCl; 
w/v), a slight decrease in the total area was observed (Fig. 2C), although particular VOMs, such as dimethylsulfide 
and isoprene, have better responses under higher ionic strengths (Supplementary Fig. 1). Considering the total 
area, a concentration of 20% NaCl (w/v) was selected for the extraction of urinary VOMs.
Sampling Headspace. Since NTME is an exhaustive technique, the sample headspace volume that is loaded 
through the sorbent is proportional to the response until the sorbent saturation is reached (breakpoint). Thus, by 
increasing the headspace volume of the sample, we will increase the extraction efficiency. In the evaluation of this 
parameter, the equilibration time and sample flow are also important parameters and should be considered. The 
first of these interfering factors was assayed in this work, while the second, the sample flow, was used as described 
by Trefz et al.15, that previously optimized this condition for the exhaled breath analysis using NTME15. Also in 
that report, the authors demonstrated that the extractive response of the sorbent was greater when larger sam-
ple headspace volumes were used, at least for the model metabolites isoprene, pentane, toluene and pentanal15. 
Figure 2. Optimization of different parameters affecting NTME: pH (A), extraction temperature (B), ionic 
strength through NaCl concentration (C), volume of the sample headspace (D), equilibration time (E), sample 
stirring (F) and volume (G). The number of VOMs identified in each experimental condition is also indicated in 
the top of each bar.
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Furthermore, the breakthrough volume of this type of NTD was not reached up to a headspace volume of 60 mL15 
and a linear response was obtained in this range. Our results show a considerable increase in the number and total 
area of the VOMs extracted between 10 and 30 mL of headspace, whereas the gain is very moderate up to 40 mL 
of sample headspace and there is a decrease in the total area of the metabolites extracted (and less 2 VOMs iden-
tified) for 50 mL of headspace (Fig. 2D). Based on the obtained results, and in order to minimize the extraction 
time and increase the reusability of the sorbents, 30 mL was selected as the appropriate headspace sample volume.
Equilibration Time. The equilibration time of the urine sample with its headspace affects the VOMs dif-
fusion to the vapor phase. Analysis of the results obtained shows an incremental response of the total area and 
number of metabolites up to 40 min of equilibration (Fig. 2E). For a longer equilibration time of 60 min, the 
increase in the total area is not significant and the number of compounds decreases from 88 to 84. This suggests 
that some metabolites degradation may occurs as result of the prolonged time under heating and stirring condi-
tions. Furthermore, the behaviour of specific VOMs analysed individually is not uniform, with better responses 
observed with 60 min of equilibration for (+) - 4-carene and dimethylsulfide, the opposite for acetone and 
2-butanone and irregular variations for toluene, phenol, isoprene and 2-pentanone (Supplementary Fig. 1). An 
equilibration time of 40 min was therefore selected as the most favourable.
Sample Stirring. Constant and efficient sample stirring facilitates sample homogenization16 and VOMs 
difusion from the liquid to the vapor phase, thus reaching equilibrium more quickly13. Our results show that a 
constant sample stirring at 800 rpm contributes to a considerable improvement in the extraction efficiency of the 
methodology by comparison with a no stirring approach. This is clearly expressed by the large increase (almost 
two times) in the number of extracted metabolites and total area (Fig. 2F). An equivalent result was obtained for 
several metabolites analysed individually (data not shown).
Sample Volume. In the evaluation of the optimum sample volume, we assayed 2, 4 and 8 mL of urine. The 
results obtained reveals a small increase in the total area and number of VOMs identified from 2 to 4 mL, but no 
significant gain with 8 mL samples (Fig. 2G). When this analysis was detailed to specific VOMs, heterogeneous 
variations were obtained for the selected metabolites (Supplementary Fig. 1). Considering these results, particu-
larly the negligent gain in the extraction efficiency by doubling the sample volume from 4 mL to 8 mL, the lower 
sample volume was selected as the most suitable for the methodology being optimized. This selection also allows 
a significant reduction in the sample residues produced.
Storage Time. The stability of the extracted VOMs in the sorbent as a function of the storage time (0–72 h) 
was also evaluated. This parameter is very relevant because samples are collected outside the laboratory, mostly in 
clinical facilities, where patients are observed. In this context, the possibility of performing in situ sampling and 
store the extracted analytes in the NTDs for later analysis, therefore avoiding the transport of biological samples 
from the collection point to the lab, would be a major advantage. The results obtained were very interesting as 
we verified that during the first 12 hours of storage there are no significant differences (p < 0.05) in terms of total 
areas, while after 24 hours, the decrease in the metabolite stability is marginal (decrease of less than 10% total 
area compared to the starting point - VOMs extracted and analysed after sample collection). Even after 48 and 
72 hours of extraction, the loss of extracted analytes is about 15% over the initial period, revelling therefore a high 
stability and reliability in the use of the NTDs as a sampling and storage device for the VOMs extracted at least up 
to 3 days after extraction (Fig. 3). This study was further extended to the analysis of a set of representative VOMs. 
As can be observed in Fig. 3, the decrease in total areas obtained for the selected metabolites is not appreciable, 
confirming the high stability of the selected metabolites in the sorbent during the period considered.
VOMs Profile of Lung Cancer Patients. The urinary VOMs profile of LC was established using NTME 
followed by high-resolution GC-MS to process 30 urine samples from healthy subjects (CTRL) and 17 urine sam-
ples from LC patients. The typical chromatograms of the volatile urine profile of subjects from each study group 
is presented in the Supplementary Fig. 2.
The analysis of the chromatograms obtained allowed the identification of 98 VOMs with a frequency of occur-
rence (FO) higher than 90% in the volatile composition of the urine of all samples used in this study. Table 1 
summarizes the metabolites identified for each group, the chromatographic data and the possible origin17.
The metabolites identified in CTRL and LC urine samples span diverse chemical families, being the most 
representative the ketones, in addition to sulfuric, benzenic, furanic and terpenic compounds. Figure 4 shows the 
distribution of the metabolites identified in the groups under study according to their chemical families. As can 
be easily observed, the urinary profiles of both groups are dominated by sulphur compounds and ketones (each 
class representing nearly 30% of the total area), with the remaining classes representing less than 10% of the total 
area obtained in each group. The only exception are benzenes, which are highly abundant in the control samples 
(around 30% of the total area obtained), while in the patients group, only a third of the equivalent representa-
tiveness was found. In the same direction, terpenics and alcohols are significantly more abundant in the control 
group. Phenolics and aldehydes, in turn, are more abundant in the LC than in the control group. These volatomic 
differences are eventually related with the altered metabolic activity that cancers cells have in comparison with 
the normal cells. Nevertheless, external factors contributing with exogenous VOMs must be also considered 
as important interferent factors5,6. And this problem cannot be overcome just by discarding such metabolites, 
because for many of them it is not possible to associate a unique origin, being very difficult to completely elucidate 
their metabolic pathway6,18,19.
Statistical Analysis. Following the characterization of the urinary volatile profiles of LC and CTRL subjects, 
the data obtained was processed with different statistical tools to assess the existence of discriminative models 
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able to distinguish LC from CTRL samples. In addition to the procedures described in the experimental section, 
and to try to obtain more robust and meaningful models, only the VOMs identified with a FO of at least 90% were 
considered in the statistical analysis. Moreover, the VOMs unambiguously reported in the literature17 as exoge-
nous were also discarded. Firstly, a variable normalization was applied to the data matrix to obtain a homogene-
ous distribution. This procedure reduced the size of the data matrix by eliminating redundant variables that do 
not contribute to differentiate the groups being analysed. Following this, a multivariate analysis using supervised 
partial least square discriminant analysis (PLS-DA) models20,21 was performed with the MetaboAnalyst 3.0 web 
based tool22. The statistical model obtained segregates LC an CTRL samples in two clusters corresponding to the 
cancer and non-cancer samples analysed (Fig. 5). Additionally, top 29 VOMs differentially expressed were found 
with variable importance in projection (VIP) > 1 (Table 2). Among these, several VOMs have been previously 
involved in the discrimination of different clinical conditions. Hexanal, as well as other aldehydes, for instance, 
has been already reported by several authors as discriminant metabolites for LC23–25. In turn, Rudnicka et al. 
showed that, although carbon disulfide was present in the volatile profile of healthy individuals and smokers, 
it has a higher significance in LC, with a considerably higher response in the patients26. A similar result was 
reported by Buszewski et al.27 when comparing the volatile composition of normal and stomach cancer tissue. 
Regarding 2-heptanone, Hanai et al.28 identified this ketone in the urine and culture of rats LC cell lines, with a 
higher abundance than the respective control groups. Finally, to check the robustness of statistic model obtained, 
a random permutation test with 100 permutations was performed with PLS-DA model. The permutation test 
yielded a R2 (Goodness of fit) of 0.915 and a Q2 (Predictive ability) of 0.760, indicating that the model is not over 
fitted and has good predictive ability to distinguish between the studied groups. It should be highlighted, however, 
that this is just a proof of concept study involving a limited number of samples. To be able to extrapolate the dis-
crimination power for LC diagnosis, broader and extensive studies with a statistical significant number of samples 
and independent patient cohorts are mandatory. The methodology reported here constitutes a breakthrough 
given the superior sampling and storage abilities of the NTDs and the broader coverage of the volatomic profiles 
obtained and may therefore help to reach our ambitious aims.
Figure 3. Analysis of the VOMs storage stability in the triple NTD up to 72 h upon extraction.
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VOMs
RT 
(min) KI Exp KI Lit
LC CTRL
Possible OrignFO Total Area FO Total Area
1 Pentane 4.38 660 650 82 9.3E + 04 100 6.3E + 04 End/Ex
2 Methyl chloride 4.49 671 — 71 7.6E + 05 100 1.5E + 05 End/Ex
3 Hexane 4.54 676 600 100 7.5E + 04 97 4.9E + 04 End/Ex
4 Ethyl ether 4.60 682 640 94 1.7E + 04 87 1.3E + 04 Unkn
5 Isoprene 4.67 689 633 100 9.4E + 05 100 8.0E + 05 End
6 Methanethiol 4.82 703 702 100 1.6E + 06 100 1.3E + 06 End
7 Acetaldehyde 4.85 706 703 88 3.1E + 06 97 4.9E + 05 End/Ex(DM)
8 Carbon disulfide 5.08 726 723 100 1.1E + 06 100 2.0E + 05 Ex
9 Dimethyl sulfide 5.21 737 737 94 6.3E + 04 100 8.2E + 04 End/Ex(DM)
10 trans-2-Methyl-1,3-pentadiene 5.45 757 760 100 9.4E + 04 83 1.4E + 04 Unkn
11 Furan 5.59 768 760 100 1.9E + 07 100 2.0E + 07 End
12 Acetone 5.84 788 785 100 2.6E + 07 100 3.7E + 07 End(M)
13 Tetrahydro-2,2,5,5-tetramethylfuran 6.42 830 — 100 5.2E + 05 93 4.6E + 06 Unkn
14 2-Methylfuran 6.59 842 843 100 3.2E + 06 100 3.0E + 06 End
15 3-Methylfuran 7.12 876 877 82 5.3E + 05 97 2.0E + 06 Ex(F)
16 2-Butanone 7.20 881 881 94 3.8E + 06 100 5.1E + 06 End
17 3-Methyl-2-butanone 7.90 915 918 100 8.5E + 05 90 1.4E + 06 End
18 Benzene 8.22 927 924 100 6.3E + 04 80 2.8E + 05 Ex(E)
19 2,5-Dimethylfuran 8.59 940 943 100 5.5E + 05 80 6.7E + 05 Ex(F)
20 2-Ethylfuran 8.62 941 941 100 7.0E + 05 70 3.8E + 05 Ex(F)
21 1,6-Dimethylhepta-1,3,5-triene 8.71 944 — 100 4.1E + 05 93 2.3E + 05 Unkn
22 1,2,5,5-Tetramethyl-1,3-cyclopentadiene 8.99 953 — 100 2.0E + 05 100 1.5E + 05 Unkn
23 5-tert-Butyl-1,3-cyclopentadiene 8.93 951 — 94 4.0E + 05 63 3.1E + 05 End/Ex(F)
24 2-Pentanone 9.37 966 969 100 1.4E + 07 100 1.7E + 07 Ex(F)
25 2,4-Dimethyl-3-pentanone 10.15 989 995 100 4.7E + 06 100 1.3E + 06 End/Ex(F)
26 2-Hexanone 11.10 1001 1082 100 9.0E + 05 100 4.9E + 05 End
27 3,3-Dimethyl-6-methylenecyclohexene 10.78 1006 — 100 1.6E + 05 93 9.7E + 04 Unkn
28 3-Methyl-2-pentanone 10.91 1008 1005 100 1.2E + 06 100 1.1E + 06 End/Ex(F)
29 Thiophene 11.25 1016 1017 100 1.9E + 05 100 2.4E + 05 End/Ex (F)
30 1,3-Dimethyl-1-cyclohexene 11.66 1024 — 100 9.5E + 05 100 8.8E + 05 Unkn
31 Toluene 12.06 1032 1033 100 8.7E + 05 100 2.1E + 06 Ex(PF)
32 3-Hexanone 12.71 1044 1047 100 7.1E + 05 100 1.7E + 06 End
33 2-Methyl-3-hexanone 12.93 1044 — 94 5.6E + 05 60 5.9E + 05 Unkn
34 2-Ethyl-4-methylimidazole 12.97 1049 — 100 1.5E + 05 100 2.4E + 05 Unkn
35 Dimethyl disulfide 13.90 1065 1065 100 9.8E + 07 100 1.0E + 08 End
36 Hexanal 14.52 1075 1075 100 9.3E + 05 93 3.4E + 05 End
37 2-Methylthiophene 14.99 1083 1085 100 1.7E + 05 97 1.9E + 05 Ex(F)
38 2-Methyl-(E)-2-butenal 15.41 1089 1088 100 1.4E + 05 83 1.0E + 05 End/Ex(F)
39 6,6-Dimethylhepta-2,4-diene 15.53 1091 — 100 1.3E + 05 93 7.1E + 04 Unkn
40 2-Ethyl-5-methylfuran 15.64 1092 1034 94 7.8E + 05 73 9.0E + 04 End/Ex(F)
41 2,2,6-Trimethyl-6-vinyltetrahydropyran 15.83 1095 1095 100 1.4E + 05 100 2.5E + 05 End/Ex(F)
42 7,7-Dimethyl-9-oxatricyclo[6.2.2.0(1,6)]dodecan-10-one 17.21 1114 — 94 1.5E + 05 93 1.2E + 05 Unkn
43 4-Heptanone 17.42 1117 1118 100 5.0E + 07 100 3.0E + 07 End
44 p-Xylene 18.05 1124 1123 100 1.1E + 05 100 2.4E + 05 Unkn
45 1,5,5-Trimethyl-6-methylene-cyclohexene 18.21 1126 — 100 1.7E + 05 100 1.6E + 05 Unkn
46 Ethyl methyl disulfide 18.51 1130 1141 94 6.5E + 04 97 5.3E + 04 Ex(F)
47 α-Phellandrene 19.21 1138 1143 76 3.0E + 04 90 9.5E + 04 End/Ex(F)
48 3-Heptanone 19.60 1143 1148 100 6.6E + 04 97 9.3E + 04 End/Ex(F)
49 α-Terpinene 20.27 1150 1159 100 7.1E + 05 100 2.4E + 06 End/Ex(F)
50 1,4-Cineole 20.80 1156 1164 100 4.2E + 05 100 1.2E + 06 End/Ex(F)
51 2-Heptanone 22.37 1172 1173 100 1.0E + 06 100 4.8E + 05 End
52 Eucalyptol 23.33 1181 1183 82 2.7E + 05 97 4.7E + 05 Ex(D)
53 1-Ethyl-3-methylbenzene 24.54 1192 1200 88 9.2E + 04 90 2.1E + 05 Unkn
54 2-Pentylfuran 25.55 1201 1203 100 8.7E + 05 97 4.9E + 05 End/Ex(F)
55 γ-Terpinene 25.88 1205 1213 100 3.1E + 05 100 1.2E + 06 Ex(F)
56 3,4-Dimethylthiophene 28.15 1226 1240 100 3.7E + 05 100 1.2E + 06 Ex(F)
Continued
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Conclusions
To the best of our knowledge, this is the first study reporting the high throughput potential of NTME combined 
to GC-MS to characterize the volatomic profile of urine samples without complicated pre-treatments, so could 
be a versatile tool for future application, providing a good technical advance. In this context, different key param-
eters of the extraction procedure were evaluated and optimized according to the nature of the sample and its 
volatile composition. The optimized experimental layout involves a DVB/CarX/Car1000 NTD to extract 40 mL 
headspace of a 4-mL acidified urine added NaCl 20% (m/v), during 40 min at temperature of 50 ± 1 °C. The meth 
odology was applied to 47 urine samples (30 CTRL samples and 17 LC samples), and a good dicrimination 
VOMs
RT 
(min) KI Exp KI Lit
LC CTRL
Possible OrignFO Total Area FO Total Area
57 o-Cymene 28.99 1234 1248 100 1.3E + 07 100 7.0E + 07 Ex(F)
58 Isoterpinolene 29.87 1242 1270 65 1.5E + 05 97 8.0E + 05 End/Ex(F)
59 Methyl allyl disulfide 31.13 1253 1253 100 4.6E + 06 100 2.8E + 06 Ex(F)
60 1,3-Dithiane 31.64 1257 1296 100 6.5E + 05 100 8.9E + 05 End/Ex(F)
61 1,3-Dimethyl-2-ethylbenzene 34.74 1281 1347 100 9.5E + 06 83 1.5E + 07 Unkn
62 2,2,6-Trimethylcyclohexanone 35.21 1284 1284 100 8.9E + 04 93 8.7E + 04 End/Ex(F)
63 1,2,3-Trimethylbenzene 36.63 1295 1295 100 3.3E + 05 100 4.4E + 05 Unkn
64 2-methoxy-5-methyl-Thiophene 39.71 1321 — 100 1.4E + 05 93 7.7E + 04 Unkn
65 Dimethyl trisulfide 42.37 1343 1343 100 7.5E + 06 100 8.4E + 06 End/Ex(M)
66 2-Methyl-5-(methylthio)furan 44.17 1358 — 100 1.1E + 06 97 5.9E + 05 Ex(F)
67 Isophorone 46.55 1376 1541 100 5.5E + 05 93 1.7E + 05 End/Ex(F)
68 2,3-Dihydro-1,1,5,6-tetramethyl-1H-indene 48.96 1393 — 82 9.9E + 05 100 1.1E + 06 Unkn
69 1,1,6,7-Tetramethyl-Indan 49.61 1398 — 65 7.1E + 05 93 1.1E + 06 Unkn
70 p-Cymenene 50.24 1400 — 100 4.4E + 06 97 1.8E + 07 End/Ex(F)
71 Durene 55.67 1449 1446 94 5.8E + 05 90 1.4E + 06 Unkn
72 Acetic acid 58.07 1468 1465 94 1.4E + 06 93 1.5E + 06 End/Ex(DM)
73 1,2,5,5,6,7-Hexamethylbicyclo[4.1.0]hept-2-en-4-one 60.25 1484 — 94 4.5E + 05 100 9.6E + 05 Unkn
74 1-(4-Methoxyphenyl)-1,3-butanedione 60.57 1487 — 100 2.7E + 05 100 5.4E + 05 Unkn
75 2-Ethyl-1-hexanol 61.07 1490 1490 100 2.9E + 05 60 1.1E + 05 End/Ex(F)
76 m-Anisalcohol 61.85 1496 — 100 3.1E + 05 93 3.6E + 05 Ex(F)
77 2-Acetylfuran 61.98 1497 1498 100 3.7E + 05 90 4.6E + 05 Ex(F)
78 5-Methylfurfural 69.92 1565 1567 100 6.5E + 04 60 5.6E + 04 Ex(F)
79  trans-(-)-5-Methyl-3-(1-methylethenyl)-cyclohexene 69.91 1565 — 100 6.4E + 04 43 4.6E + 04 Unkn
80 1,1,4,5-tetramethyl-2,3-dihydro indene 75.43 1613 — 100 2.1E + 05 60 1.8E + 05 Unkn
81 1,1,3-Trimethyl indane 78.58 1648 — 100 1.3E + 05 70 1.7E + 05 Unkn
82 Dehydro-Ar-ionene 83.90 1706 1712 100 1.0E + 07 100 4.6E + 06 Ex(F)
83 α-Curcumene 87.38 1764 1764 71 6.5E + 04 100 3.0E + 06 Unkn
84 1-(2,6,6-Trimethyl-1,3-cyclohexadien-1-yl)-2-buten-1-one 89.92 1810 1801 94 1.9E + 05 63 1.8E + 05 End
85 1,1,3-Trimethyl-1H-indene 90.57 1829 — 94 2.5E + 05 77 7.0E + 05 Unkn
86 2,5,8-Trimethyl-1,2-dihydronaphthalene 90.88 1838 1999 94 5.9E + 05 33 3.3E + 05 Unkn
87 Guaiacol 91.91 1868 1868 100 5.6E + 05 100 4.4E + 05 End
88 α-Calacorene 93.21 1909 1910 100 6.6E + 05 100 1.5E + 06 End/Ex(F)
89 Phenol 95.12 2009 2009 100 2.1E + 06 100 1.2E + 06 End/Ex(E)
90 p-Cresol 96.37 2074 2074 100 1.5E + 07 100 1.1E + 07 End/Ex(M)
91 1-(2,3,6-Trimethylphenyl)-3-buten-2-one 97.02 2107 2180 100 3.5E + 05 80 2.6E + 05 Unkn
92 p-Ditolylmethane 98.25 2169 — 100 1.1E + 05 83 1.4E + 05 Unkn
93 Carvacrol 98.50 2182 2183 100 7.0E + 05 90 4.8E + 05 End/Ex(F)
94 4-tert-Butyl-2-Bromophenol 98.72 2193 — 100 4.1E + 05 97 1.9E + 05 End/Ex(F)
95 Cadalene 98.94 2204 2203 100 2.6E + 05 97 4.7E + 05 Unkn
96 4-tert-Butylphenol 99.83 2248 — 100 1.1E + 06 100 5.8E + 05 End/Ex(F)
97 3,5-Di-t-butylphenol 100.72 2256 2310 71 6.1E + 04 100 1.4E + 05 End
98 Benzoic Acid 102.75 2402 2405 76 1.4E + 05 97 1.2E + 05 Ex(FM)
Table 1. VOMs identified in urine samples from LC and CTRL groups by NTME/GC–MS methodology 
and respective possible origin (End - VOM endogenously produced, Ex – VOM resulting from exogenous 
sources, as diet (F), microbial (M), drug metabolism (D), environmental contamination (E), according to the 
data available in the human metabolome database17, Unkn – VOM whose origin is currently unknown). RT- 
Retention time (min); KI – Kovats Index (Exp – experimental, Lit – theoretical KI values reported in literature). 
FO – Frequency of occurrence.
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between both groups based in the volatomic profiles was obtained upon application of MVSA to the data 
matrix. This proof of concept study demonstrates the advantages of NTME/GC-MS in the characterization of 
complex urinary volatile profiles in addition to the potential of the methodology as useful platform towards the 
non-invasive disease diagnosis.
Materials and Methods
Chemicals and Materials. Hydrochloric acid (HCl), sodium chloride (NaCl), all the standards used for 
VOMs confirmation (purity higher than 98.5%) and the n-alkanes mixture containing C8–C20 straight-chain 
alkanes in hexane were obtained from Sigma-Aldrich (St. Louis, MO, USA). Helium, ultra-pure grade (Air 
Liquide, Portugal) was used as carrier gas in the GC system. Clear glass screw cap vials for extraction with 
PTFE/silica septa were purchased from Supelco (Bellefonte, PA, USA). The NTDs used in this work, “NeedleEx”, 
were custom manufactured by Shinwa Ltd., Japan (60 mm × 0:41 mm id, 0.72 mm od, triple bed configuration 
Divinylbenzene/Carboxen X/Carbopack 1000 - DVB/CarX/Car1000) and purchased from PAS Technology 
(Magdala, Germany). Prior to their use, NTDs were conditioned in a heating device (PAS Technology, Magdala, 
Germany) at 250 °C, under permanent helium flow for at least 20 h to eliminate any contaminations from the 
manufacturing process or shipping. Afterwards, both ends of the needles were sealed with Teflon caps and stored. 
Before being used, the NTDs were conditioned again for 30 min in the heating device.
Subjects and Urine sampling. Thirty healthy individuals (14 males and 16 females, age = 18–65 years; 
control group – CTRL) without any known pathology recruited at the Blood Transfusion Medicine Service of 
Dr. Nélio Mendonça Hospital - HCF) and 17 LC patients (11 males and 6 females, age = 46–80 years, recruited 
Figure 4. Characterization of the VOMs profiles obtained for LC and CTRL groups by chemical family. These 
simplified profiles were obtained using only the VOMs with a frequency of occurrence (FO) above 90%. Legend: 
Acids - Organic acids, Alc – Higher Alcohols, Ald - Aldehydes, Benz - Benzene derivatives, CTRL – control, Est 
– Esters, Fur – Furans, HC – Hydrocarbons, LC – patients with colon cancer, Napht - Naphthalene derivatives, 
Oth – Others, Phen – Phenols, Sulf – Organosulphurs, Terp - Terpene derivatives.
Figure 5. Application of PLS-DA to the experimental data obtained. Legend: CTRL – control samples, LC – 
lung cancer samples, PLS-DA - supervised partial least square discriminant analysis.
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at the Haemato-Oncology Unit of HCF), were randomly selected among the volunteers (Table 3). Participants 
were given sterile and disposable glass bottle collectors and instructed to collect the first urine in the morning 
after the rejection of the first urine stream. All participants were fully informed of the objectives of the study and 
signed the informed consent before donating the urine samples. After collection, each sample was individually 
homogenized, aliquoted in 5 mL ambar glass vials and stored at −80 °C until analysis. This study was previously 
approved by the Ethics Committee of HCF.
Optimization of NTME extraction. To increase the NTME efficiency, different key parameters were opti-
mized according to the characteristics of the sample and extractive methodology6,29. This included (i) the pH of 
the sample (acid – pH 2, basic – pH 11, and neutral – pH 7), (ii) the extraction temperature (30 °C, 40 °C, 50 °C 
to 60 °C), (iii) the ionic strength (0, 10%, 20% and 30% NaCl, w/v), (iv) sample headspace volume (10, 25, 30, 40 
and 50 mL), (v) the equilibration time (5, 10, 20, 40, 50 and 60 min), (vi) sample stirring (0 and 800 rpm) and (vii) 
sample volume (2, 4 and 8 mL) were tested using an univariate procedure to achieve extraction conditions suitable 
for this application (lowest sample volume, preferentially near room temperature and reasonable equilibration 
time). In this study, we also evaluated the storage time of the VOMs in the NTD (2, 4, 6, 12, 24, 48 and 72 hours 
after the NTME extraction). All extractions were performed in duplicate.
VOMs Comp. 1 Comp. 2 Comp. 3
Methyl chloride 1.10 1.03 1.00
Acetaldehyde 1.34 1.33 1.34
Carbon disulfide 1.34 1.25 1.21
Dimethyl sulfide 1.19 1.16 1.19
Acetone 0.86 0.92 1.00
2-Butanone 0.99 0.95 0.99
1,6-Dimethylhepta-1,3,5-triene 1.77 1.66 1.64
2,4-Dimethyl-3-pentanone 1.11 1.04 1.03
3,3-Dimethyl-6-methylenecyclohexene 1.64 1.52 1.50
Thiophene 1.09 1.10 1.10
3-Hexanone 1.17 1.18 1.18
Hexanal 1.02 0.96 0.96
2-Ethyl-5-methylfuran 1.17 1.14 1.11
2,2,6-Trimethyl-6-vinyltetrahydropyran 1.31 1.34 1.30
α-Phellandrene 1.73 1.64 1.61
α-Terpinene 1.56 1.52 1.49
1,4-Cineole 1.11 1.14 1.13
2-Heptanone 1.06 1.04 1.03
1-Ethyl-3-methylbenzene 1.60 1.49 1.48
Isoterpinolene 1.47 1.48 1.46
1,2,3-Trimethylbenzene 1.17 1.16 1.13
2,3-dihydro-1,1,5,6-tetramethyl-1H-indene 1.68 1.59 1.59
α-Curcumene 1.50 1.40 1.37
1,1,3-trimethyl-1H-indene 1.17 1.25 1.23
α-Calacorene 1.26 1.28 1.26
p-Cresol 1.65 1.56 1.52
Carvacrol 1.19 1.17 1.22
4-tert-Butylphenol 1.68 1.56 1.52
3,5-Di-t-butylphenol 2.16 2.21 2.15
Table 2. List of VIP VOMs obtained following PLS-DA analysis (score >1). Comp. 1 – Component 1; Comp. 
2 – Component 2; Comp. 3 – Component 3.
# Diagnose Number of samples Gender Age (years) Smokers
CTRL Control 30 14 Male/16 Female 18–65 6
LC Lung Cancer 17 11 Male/6 Female 46–80 0*
Table 3. Characterization of the groups of subjects recruited for this study, by diagnose, number of samples, 
gender, age and smoker habits, All the samples were collected after the approval by ethics committee of Hospital 
do Funchal, Madeira, Portugal. CTRL –Healthy individuals, LC – Lung Cancer patients, *All 17 subjects are ex-
smokers.
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NTME extraction. Following the optimization step, 4 mL of urine sample was insert in 20 mL tubes (extrac-
tion tubes - ETs) and added 0.5 mL HCl 5 M to acidify the sample (pH = 2). The pH was verified with the aid of 
a pH meter (Hanna Instruments) with a clean electrode. After the measurements, the electrode was carefully 
cleaned to avoid contamination between samples. To promote the salting-out effect, facilitating the transference 
of the urinary VOMs for the headspace, 20% NaCl (w/v) were added, the ET sealed, and the system equilibrated 
for 40 min at 50 ± 1 °C. Then, the NTDs pre-attached to a disposable 1 mL syringe were insert into the headspace 
of the ETs and 40 mL of the gas phase were manually loaded through the sorbent (40 withdraw-loading cycles, 
average speed 10 ± 2 mL/min). After the extraction, the syringe was discarded and the NTD was sealed in both 
ends with PTFE caps. Finally, the NTD was injected in the GC-MS at 250 °C for 30 seconds for thermal desorp-
tion of the extracted VOMs. Before the next extraction, the sorbent was reactivated by placing the NTDs in a 
conditioner at 250 °C under constant flow of helium (purity 5.0, Air Liquid, Portugal) at a constant pressure of 
1 bar for 30 min.
Gas chromatography-mass spectrometry analysis (GC-MS). The analysis was carried out with an 
Agilent 6890N gas chromatograph system (Agilent Technologies, Palo Alto, CA, USA) coupled with an Agilent 
5975 quadrupole inert mass selective detector. The separation of the extracted compounds was performed on 
a BP-20 fused silica capillary column (60 m × 0.25 mm I.D. × 0.25 µm film thickness). Splitless injection was 
employed using helium as carrier gas at a constant flow rate of 1.0 mL/min. Oven temperature conditions were: 
45 °C (held for 2 min), followed by a gradient temperature ramp from 45 °C to 60 °C, held for 1 min at a rate 
of 0.7 °C/min, followed by a flow rate of 1.0 °C/min until 110 °C (held for 1 min); then a flow rate of 3.0 °C/
min until 150 °C (held for 1 min) and finally from 150 °C to 220 °C held for 10 min at a rate of 15 °C/min. The 
injection and ion source temperatures were 250 °C and 230 °C, respectively. The mass spectra of the compounds 
were acquired in electron-impact (EI) mode at 70 eV. The electron multiplier was set by the auto tune proce-
dure. Data acquisition was performed in scanning mode (mass range m/z = 35–300 amu; six scans per second). 
Chromatograms and spectra were recorded and processed using the Enhanced ChemStation software for GC-MS 
(Agilent Technologies, Palo Alto, CA, USA). VOMs identification was based on the comparison between the 
GC retention times (RT) of the chromatographic peaks with those, when available, of authentic standards run 
under the same conditions. MS fragmentation patterns were compared with those of pure compounds, and mass 
spectrum database search was performed using the National Institute of Standards and Technology (NIST) MS 
05 spectral database. Finally, confirmation also involved the determination of the RI of each peak of C8–C20 
n-alkanes series. Once again, the values were compared, when available, with values reported in the literature for 
similar chromatographic columns. Chromatographic peak areas, expressed in arbitrary units (a.u.) of area were 
determined using the FullScan chromatogram, and were used as an indirect approach to estimate the relative con-
tent of each volatile metabolite. For semi-quantification purposes, each sample was injected in triplicate, and the 
chromatographic peak areas (as kcounts amounts) were determined by a reconstructed full-scan chromatogram 
using for each compound some specific quantification ions: these corresponded to base ion (m/z 100% intensity), 
molecular ion (M+), and another characteristic ion for each molecule.
Multivariate statistical analysis (MVSA). In order to identify potential discriminative features for the 
selected groups (LC and CTRL), the statistical data analysis was carried out using the web based application, 
Metaboanalyst 3.022. The data was normalized by the median, auto scaled and subjected to multivariate statistical 
analysis. Partial least squares-discriminant analysis (PLS-DA) was then used to visualize the separation between 
LC and CTRL groups and to identify set of VOMs able to discriminate between the two groups.
Ethical approval. The study was approved by ethics committee of Hospital do Funchal, Madeira, Portugal.
Informed consent. Prior informed consent was obtained from all the participants in the study with institu-
tional review approval.
Research involving human participants and/or animals. All protocols and procedures were adhered 
to institutional ethical standards and/or research committee and with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards.
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